Home
Clinical Trials
A Study to Evaluate the Treat...

A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Last Updated: 2008-03-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, open-label, single arm Phase 1/2 study evaluating the feasibility, safety, and tolerability of a series of 16 immunizations of Id-KLH with GM-CSF in patients with previously untreated B-CLL. The length of the controlled portion of the study is two years. The study will be conducted at investigative sites in the United States.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma

NCT01766583

Relapsed/Refractory B-cell Lymphoma

COMPLETED PHASE1

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia

NCT00019032

Leukemia

COMPLETED PHASE1

Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00058396

Leukemia Lymphoma

COMPLETED PHASE1

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00324831

Lymphoma

SUSPENDED PHASE3

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

NCT06935136

CAR-T Cell Therapy High-risk Large B-cell Lymphoma (LBCL)

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

B-Cell Chronic Lymphocytic Leukemia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MyVax

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have signed a written informed consent
* B-CLL diagnosis
* Rai Stage 0, I, or II
* Previously untreated
* Be able to watch and wait for approximately 8 months following submission of blood (or tissue) while Id-KLH is being manufactured

Exclusion Criteria

* Anti-leukemia treatment prior to beginning immunization
* Anti-leukemia treatment other than Id-KLH during immunizations
* Prior malignancy (excluding basal cell carcinoma and cervical carcinoma in situ)
* Pregnant or lactating
* Patients with known autoimmune disease (including previously treated autoimmune hemolytic anemia or immune thrombocytopenia)
* Participation in any other clinical trial in which an investigational agent is administered

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers